Cost-Effectiveness of Biologics for Allergic Diseases

被引：23

作者：

Wu, Ann Chen ^{[1
,2
]}

Fuhlbrigge, Anne L. ^{[3
]}

Robayo, Maria Acosta ^{[1
,2
]}

Shaker, Marcus ^{[4
,5
,6
,7
]}

机构：

[1] Harvard Med Sch, Ctr Healthcare Res Pediat, Dept Populat Med, Boston, MA USA

[2] Harvard Pilgrim Hlth Care Inst, Boston, MA USA

[3] Univ Colorado, Sch Med, Pulm Sci & Crit Care Med, Dept Med, Aurora, CO USA

[4] Dartmouth Hitchcock Med Ctr, Sect Allergy & Immunol, Lebanon, NH 03766 USA

[5] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA

[6] Geisel Sch Med Dartmouth, Dept Med, Hanover, NH USA

[7] Geisel Sch Med Dartmouth, Dept Community & Family Med, Hanover, NH USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | 2021年 / 9卷 / 03期

关键词：

Biologics; Monoclonal antibodies; mAbs; Cost-effectiveness; Allergic disease; ANTI-IGE ANTIBODY; JOINT TASK-FORCE; QUALITY-OF-LIFE; ANTI-IL-5 MEPOLIZUMAB THERAPY; ANTIIMMUNOGLOBULIN-E ANTIBODY; CHRONIC SPONTANEOUS URTICARIA; LONG-TERM CONTROL; MONOCLONAL-ANTIBODY; SEVERE ASTHMA; IMMUNOLOGY/AMERICAN-COLLEGE;

D O I：

10.1016/j.jaip.2020.10.009

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

The introduction of specific humanized monoclonal antibodies over the past 20 years has dramatically changed the treatment of allergic diseases. At present, 5 mAbs are licensed for treating moderate to severe allergic and eosinophilic asthma, atopic dermatitis, chronic spontaneous urticaria, chronic sinusitis with nasal polyps, and eosinophilic granulomatosis with polyangiitis. Given the high costs of biologics, understanding their cost-effectiveness is critical. As new biologics are developed and new indications are approved for existing biologics, the use of biologics for allergic diseases will increase. Conducting cost-effectiveness evaluations in parallel to efficacy and effectiveness trials will help patients, providers, payers, and policymakers in decision making. (C) 2020 American Academy of Allergy, Asthma & Immunology

引用

页码：1107 / +

页数：13

共 50 条

[11] COST-EFFECTIVENESS OF RARE DISEASES IN SPAIN
Pomares, E.
Uria, E.
Martinez-Rodriguez, I
Cuesta, M.
VALUE IN HEALTH, 2018, 21 : S454 - S454
[12] Cost-effectiveness analysis in infectious diseases
Paul, M.
CLINICAL MICROBIOLOGY AND INFECTION, 2010, 16 (12) : 1705 - 1706
[13] Comment on: "A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis"
Singh, Ena
PHARMACOECONOMICS, 2018, 36 (07) : 879 - 879
[14] Comment on: “A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis”
Ena Singh
PharmacoEconomics, 2018, 36 : 879 - 879
[15] ASSESSMENT OF COST-EFFECTIVENESS MODELS FOR BIOLOGICS IN THE MANAGEMENT OF PSORIATIC ARTHRITIS
Gokhale, S.
Jalapu, A.
Mallya, U.
Mpofu, S.
VALUE IN HEALTH, 2013, 16 (07) : A717 - A717
[16] ACCOUNTING FOR PARTIAL RESPONDERS IN COST-EFFECTIVENESS MODELING OF BIOLOGICS FOR PSORIASIS
Sikirica, S.
VALUE IN HEALTH, 2013, 16 (03) : A27 - A28
[17] The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
Joensuu, Jaana T.
Huoponen, Saara
Aaltonen, Kalle J.
Konttinen, Yrjo T.
Nordstrom, Dan
Blom, Marja
PLOS ONE, 2015, 10 (03):
[18] COST-EFFECTIVENESS OF BIOLOGICS FOR MODERATE TO SEVERE ULCERATIVE COLITIS IN BRAZIL
Brito, N.
Mulinari, E.
VALUE IN HEALTH, 2020, 23 : S146 - S146
[19] Biologics in Children with Allergic Diseases
Licari, Amelia
Manti, Sara
Marseglia, Alessia
De Filippo, Maria
De Sando, Elisabetta
Foiadelli, Thomas
Marseglia, Gian Luigi
CURRENT PEDIATRIC REVIEWS, 2020, 16 (02) : 140 - 147
[20] New biologics for allergic diseases
Manka, Laurie A.
Wechsler, Michael E.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (04) : 285 - 296

← 1 2 3 4 5 →